Bremelanotide (PT-141; PT141; PT 141; Vyleesi), a peptide analogue of alpha-MSH peptide acting as a melanocortin receptor agonist approved in 2019 for the treatment of hypoactive sexual desire disorder in premenopausal women. It was developed for the treatment of sexual dysfunction, hemorrhagic shock and reperfusion injury.

纯度：≥98%

CAS：189691-06-3